NAVIDEA BIOPHARMACEUTICALS I (NAVB)
US63937X2027 - Common Stock
| 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -15.18M | -11.73M | -10.72M | -10.95M | -16.11M | |||
| Depreciation Amortization | 95.82K | 76.95K | 70.39K | 144.52K | 150.38K | |||
| Change In Working Capital | 5.12M | 947.17K | 1.84M | 1.12M | 13.83M | |||
| Interest Paid | 136.43K | 9.00K | 6.00K | 8.00K | 8.00K | |||
| Other non cash items | 976.82K | 488.66K | 637.92K | 326.55K | 6.40M | |||
| OPERATING CASH FLOW | -8.99M | -10.22M | -8.17M | -9.35M | 4.28M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -390.35K | -329.42K | -413.87K | -56.70K | -46.19K | |||
| Other Investing Activity | N/A | 0.00 | 1.04K | 827.13K | 1.00M | |||
| INVESTING CASH FLOW | -390.35K | -329.42K | -412.83K | 770.43K | 953.81K | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | 1.98M | -491.78K | -2.55K | -359.06K | -395.57K | |||
| Stock Issued/Repurchased | 6.17M | 12.69M | 10.42M | 6.51M | 3.00M | |||
| Dividend Paid | N/A | N/A | N/A | N/A | N/A | |||
| Other Financing Activity | -1.01M | -87.32K | -205.05K | 0.00 | -7.15M | |||
| FINANCING CASH FLOW | 7.14M | 12.11M | 10.21M | 6.16M | -4.55M | |||
| CHANGE IN CASH | -2.24M | 1.56M | 1.62M | -2.43M | 680.88K | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -8.99M | -10.22M | -8.17M | -9.35M | 4.28M | |||
| Capital Expenditure | -390.35K | -329.42K | -413.87K | -56.70K | -46.19K | |||
| FREE CASH FLOW | -9.38M | -10.55M | -8.59M | -9.41M | 4.23M | |||
All data in USD